{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:49:32Z","timestamp":1791478172269,"version":"4.3.4"},"reference-count":58,"publisher":"American Chemical Society (ACS)","issue":"19","license":[{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"funder":[{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20242071"],"award-info":[{"award-number":["BK20242071"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473785"],"award-info":[{"award-number":["82473785"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Epidermal growth factor receptor (EGFR) kinase inhibitors have revolutionized non-small cell lung cancer (NSCLC) treatment; however, the inevitable acquired resistance necessitates alternative strategies beyond conventional inhibition. Herein, we report the discovery and optimization of VHL-recruiting PROTAC degraders targeting the EGFR. Representative compounds C4 and D4 demonstrated potent, selective, and durable degradation of EGFRDel19 (C4: DC50 = 1.41 nM, Dmax = 99%; D4: DC50 = 9.14 nM, Dmax = 98%) and EGFRL858R (C4: DC50 = 3.30 nM, Dmax = 95%; D4: DC50 = 15.2 nM, Dmax = 98%). C4 induced cell cycle arrest and apoptosis, displayed subnanomolar antiproliferative activity, and drove significant tumor regression in an HCC827 xenograft model at low intravenous doses with a reduced twice-weekly schedule. Remarkably, D4 was orally bioavailable (F = 11.3%) and blood\u2212brain barrier penetrant and completely inhibited tumor growth in vivo after oral dosing. Overall, this work provides promising starting points for next-generation EGFR-directed therapy.<\/jats:p>","DOI":"10.1021\/acs.jmedchem.6c01893","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T19:02:25Z","timestamp":1789758145000},"page":"22671-22698","source":"Crossref","is-referenced-by-count":0,"title":["Discovery of Potent and Selective VHL-Recruiting PROTAC Degraders Targeting EGFR with Improved Developability and Potent Anti-NSCLC Efficacy"],"prefix":"10.1021","volume":"69","author":[{"given":"Xiang","family":"Ni","sequence":"first","affiliation":[{"name":"China Pharmaceutical University , , ,","place":["Nanjing, China, 210009"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Li","sequence":"additional","affiliation":[{"name":"China Pharmaceutical University , , ,","place":["Nanjing, China, 210009"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinglin","family":"Tang","sequence":"additional","affiliation":[{"name":"China Pharmaceutical University , , ,","place":["Nanjing, China, 210009"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihao","family":"Qi","sequence":"additional","affiliation":[{"name":"China Pharmaceutical University , , ,","place":["Nanjing, China, 210009"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhou","sequence":"additional","affiliation":[{"name":"China Pharmaceutical University , , ,","place":["Nanjing, China, 210009"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zepeng","family":"Liao","sequence":"additional","affiliation":[{"name":"China Pharmaceutical University , , ,","place":["Nanjing, China, 210009"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyun","family":"Song","sequence":"additional","affiliation":[{"name":"China Pharmaceutical University , , ,","place":["Nanjing, China, 210009"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Miao","sequence":"additional","affiliation":[{"name":"China Pharmaceutical University , , ,","place":["Nanjing, China, 210009"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyi","family":"Zhang","sequence":"additional","affiliation":[{"name":"China Pharmaceutical University , , ,","place":["Nanjing, China, 210009"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4550-5024","authenticated-orcid":true,"given":"Sheng","family":"Jiang","sequence":"additional","affiliation":[{"name":"China Pharmaceutical University , , ,","place":["Nanjing, China, 210009"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yibei","family":"Xiao","sequence":"additional","affiliation":[{"name":"China Pharmaceutical University , , ,","place":["Nanjing, China, 210009"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8103-3603","authenticated-orcid":true,"given":"Kuojun","family":"Zhang","sequence":"additional","affiliation":[{"name":"China Pharmaceutical University , , ,","place":["Nanjing, China, 210009"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,9,18]]},"reference":[{"key":"2026100811083185000_cit1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","article-title":"Cancer statistics","volume":"75","author":"Siegel","year":"2025","journal-title":"Ca-Cancer J. Clin."},{"key":"2026100811083185000_cit2","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/nrc2088","article-title":"Epidermal growth factor receptor mutations in lung cancer","volume":"7","author":"Sharma","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"2026100811083185000_cit3","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.lungcan.2016.01.003","article-title":"Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor-mutant non-small cell lung cancer","volume":"93","author":"Tan","year":"2016","journal-title":"Lung Cancer"},{"key":"2026100811083185000_cit4","doi-asserted-by":"publisher","first-page":"6580","DOI":"10.1021\/acs.jmedchem.5b00840","article-title":"Challenges and perspectives on the development of small-molecule EGFR inhibitors against T790M-mediated resistance in non-small-cell lung cancer","volume":"59","author":"Song","year":"2016","journal-title":"J. Med. Chem."},{"key":"2026100811083185000_cit5","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41571-025-01085-z","article-title":"Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC - mechanisms and evolving treatment approaches","volume":"23","author":"Zhao","year":"2026","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2026100811083185000_cit6","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/nrc.2017.84","article-title":"Understanding and targeting resistance mechanisms in NSCLC","volume":"17","author":"Rotow","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"2026100811083185000_cit7","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12943-018-0777-1","article-title":"Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer","volume":"17","author":"Wu","year":"2018","journal-title":"Mol. Cancer"},{"key":"2026100811083185000_cit8","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s43018-021-00195-8","article-title":"Overcoming therapy resistance in EGFR-mutant lung cancer","volume":"2","author":"Passaro","year":"2021","journal-title":"Nat. Cancer"},{"key":"2026100811083185000_cit9","doi-asserted-by":"publisher","first-page":"4290","DOI":"10.1021\/acs.jmedchem.7b01310","article-title":"Recent progress of small-molecule epidermal growth factor receptor (EGFR) inhibitors against C797S resistance in non-small-cell lung cancer","volume":"61","author":"Chen","year":"2018","journal-title":"J. Med. Chem."},{"key":"2026100811083185000_cit10","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1158\/0008-5472.can-18-1281","article-title":"Novel third-generation EGFR tyrosine kinase inhibitors and strategies to overcome therapeutic resistance in lung cancer","volume":"79","author":"Murtuza","year":"2019","journal-title":"Cancer Res."},{"key":"2026100811083185000_cit11","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1021\/acs.jmedchem.1c00876","article-title":"Emerging approaches to overcome acquired drug resistance obstacles to osimertinib in non-small-cell lung cancer","volume":"65","author":"Shaikh","year":"2022","journal-title":"J. Med. Chem."},{"key":"2026100811083185000_cit12","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"Be\u0301ke\u0301s","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"2026100811083185000_cit13","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41568-025-00817-8","article-title":"Targeted protein degradation for cancer therapy","volume":"25","author":"Hinterndorfer","year":"2025","journal-title":"Nat. Rev. Cancer"},{"key":"2026100811083185000_cit14","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.chembiol.2017.09.009","article-title":"The advantages of targeted protein degradation over inhibition: An RTK case study","volume":"25","author":"Burslem","year":"2018","journal-title":"Cell Chem. Biol."},{"key":"2026100811083185000_cit15","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1021\/acs.jmedchem.9b01566","article-title":"Discovery of potent and selective epidermal growth factor receptor (EGFR) bifunctional small-molecule degraders","volume":"63","author":"Cheng","year":"2020","journal-title":"J. Med. Chem."},{"key":"2026100811083185000_cit16","doi-asserted-by":"publisher","first-page":"8416","DOI":"10.1021\/acs.jmedchem.2c00345","article-title":"Exploring degradation of mutant and wild-type epidermal growth factor receptors induced by proteolysis-targeting chimeras","volume":"65","author":"Yu","year":"2022","journal-title":"J. Med. Chem."},{"key":"2026100811083185000_cit17","doi-asserted-by":"publisher","first-page":"113328","DOI":"10.1016\/j.ejmech.2021.113328","article-title":"Effective degradation of EGFR(L858R+T790M) mutant proteins by CRBN-based PROTACs through both proteosome and autophagy\/lysosome degradation systems","volume":"218","author":"Qu","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"2026100811083185000_cit18","doi-asserted-by":"publisher","first-page":"112199","DOI":"10.1016\/j.ejmech.2020.112199","article-title":"Design and synthesis of selective degraders of EGFRL858R\/T790M mutant","volume":"192","author":"Zhang","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"2026100811083185000_cit19","doi-asserted-by":"publisher","first-page":"127167","DOI":"10.1016\/j.bmcl.2020.127167","article-title":"Discovery and biological evaluation of proteolysis targeting chimeras (PROTACs) as an EGFR degraders based on osimertinib and lenalidomide","volume":"30","author":"He","year":"2020","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"2026100811083185000_cit20","doi-asserted-by":"publisher","first-page":"114455","DOI":"10.1016\/j.ejmech.2022.114455","article-title":"Design and synthesis of proteolysis targeting chimeras (PROTACs) as an EGFR degrader based on CO-1686","volume":"238","author":"Li","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"2026100811083185000_cit21","doi-asserted-by":"publisher","first-page":"4709","DOI":"10.1021\/acs.jmedchem.1c01827","article-title":"Discovery of potent PROTACs targeting EGFR mutants through the optimization of covalent EGFR ligands","volume":"65","author":"Zhao","year":"2022","journal-title":"J. Med. Chem."},{"key":"2026100811083185000_cit22","doi-asserted-by":"publisher","first-page":"114509","DOI":"10.1016\/j.ejmech.2022.114509","article-title":"Discovery of highly potent and selective CRBN-recruiting EGFRL858R\/T790M degraders in vivo","volume":"238","author":"Zhang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"2026100811083185000_cit23","doi-asserted-by":"publisher","first-page":"112781","DOI":"10.1016\/j.ejmech.2020.112781","article-title":"Discovery of potent small molecule PROTACs targeting mutant EGFR","volume":"208","author":"Zhao","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"2026100811083185000_cit24","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1021\/acsmedchemlett.1c00645","article-title":"Design, synthesis, and biological evaluation of novel EGFR PROTACs targeting Del19\/T790M\/C797S mutation","volume":"13","author":"Zhang","year":"2022","journal-title":"ACS Med. Chem. Lett."},{"key":"2026100811083185000_cit25","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1158\/1535-7163.mct-21-0835","article-title":"HJM-561, a potent, selective, and orally bioavailable EGFR PROTAC that overcomes osimertinib-resistant EGFR triple mutations","volume":"21","author":"Du","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"2026100811083185000_cit26","doi-asserted-by":"publisher","first-page":"7283","DOI":"10.1021\/acs.jmedchem.4c00107","article-title":"Design, synthesis, and biological evaluation of novel EGFR PROTACs targeting C797S mutation","volume":"67","author":"Zhu","year":"2024","journal-title":"J. Med. Chem."},{"key":"2026100811083185000_cit27","doi-asserted-by":"publisher","first-page":"14569","DOI":"10.1021\/acs.jmedchem.5c00693","article-title":"Discovery of a novel EGFR PROTAC degrader against C797S resistance mutation with potent antitumor efficacy in NSCLC treatment","volume":"68","author":"Wang","year":"2025","journal-title":"J. Med. Chem."},{"key":"2026100811083185000_cit28","doi-asserted-by":"publisher","first-page":"14481","DOI":"10.1002\/anie.202003500","article-title":"Mutant-selective allosteric EGFR degraders are effective against a broad range of drug-resistant mutations","volume":"59","author":"Jang","year":"2020","journal-title":"Angew. Chem. Int. Ed."},{"key":"2026100811083185000_cit29","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.lungcan.2015.01.020","article-title":"Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers","volume":"88","author":"Rangachari","year":"2015","journal-title":"Lung Cancer"},{"key":"2026100811083185000_cit30","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/jto.0000000000000069","article-title":"EGFR mutation and brain metastasis in pulmonary adenocarcinomas","volume":"9","author":"Shin","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"2026100811083185000_cit31","doi-asserted-by":"publisher","first-page":"8200","DOI":"10.1021\/acs.jmedchem.5b01073","article-title":"Discovery and evaluation of clinical candidate AZD3759, a potent, oral active, central nervous system-penetrant, epidermal growth factor receptor tyrosine kinase inhibitor","volume":"58","author":"Zeng","year":"2015","journal-title":"J. Med. Chem."},{"key":"2026100811083185000_cit32","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.str.2012.11.014","article-title":"Insights into the aberrant activity of mutant EGFR kinase domain and drug recognition","volume":"21","author":"Gajiwala","year":"2013","journal-title":"Structure"},{"key":"2026100811083185000_cit33","doi-asserted-by":"publisher","first-page":"5969","DOI":"10.1038\/s41467-022-33430-6","article-title":"A selective and orally bioavailable VHL-recruiting PROTAC achieves SMARCA2 degradation in vivo","volume":"13","author":"Kofink","year":"2022","journal-title":"Nat. Commun."},{"key":"2026100811083185000_cit34","doi-asserted-by":"publisher","first-page":"5279","DOI":"10.7150\/thno.55680","article-title":"A novel small-molecule PROTAC selectively promotes tau clearance to improve cognitive functions in Alzheimer-like models","volume":"11","author":"Wang","year":"2021","journal-title":"Theranostics"},{"key":"2026100811083185000_cit35","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1021\/acsmedchemlett.5c00768","article-title":"BBB-Permeable PROTACs: Where Do We Stand?","volume":"17","author":"Francisco","year":"2026","journal-title":"ACS Med. Chem. Lett."},{"key":"2026100811083185000_cit36","doi-asserted-by":"publisher","first-page":"5683","DOI":"10.1021\/acs.jmedchem.3c02332","article-title":"Beyond rule of five and PROTACs in modern drug discovery: Polarity reducers, chameleonicity, and the evolving physicochemical landscape","volume":"67","author":"Price","year":"2024","journal-title":"J. Med. Chem."},{"key":"2026100811083185000_cit37","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1021\/acs.jmedchem.4c02492","article-title":"Impact of linker composition on VHL PROTAC cell permeability","volume":"68","author":"Abeje","year":"2025","journal-title":"J. Med. Chem."},{"key":"2026100811083185000_cit38","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1021\/acsmedchemlett.0c00556","article-title":"Solution conformations shed light on PROTAC cell permeability","volume":"12","author":"Atilaw","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"key":"2026100811083185000_cit39","doi-asserted-by":"publisher","first-page":"16930","DOI":"10.1021\/jacs.2c05499","article-title":"Discovery of XL01126: A potent, fast, cooperative, selective, orally bioavailable, and blood-brain barrier penetrant PROTAC degrader of leucine-rich tepeat kinase 2","volume":"144","author":"Liu","year":"2022","journal-title":"J. Am. Chem. Soc."},{"key":"2026100811083185000_cit40","doi-asserted-by":"publisher","first-page":"16666","DOI":"10.1021\/acs.jmedchem.5c01497","article-title":"Linker methylation as a strategy to enhance PROTAC oral bioavailability: Insights from molecular properties and conformational analysis","volume":"68","author":"Garcia Jimenez","year":"2025","journal-title":"J. Med. Chem."},{"key":"2026100811083185000_cit41","doi-asserted-by":"publisher","first-page":"12831","DOI":"10.1021\/acs.jmedchem.1c00882","article-title":"Strategies toward discovery of potent and orally bioavailable proteolysis targeting chimera degraders of androgen receptor for the treatment of prostate cancer","volume":"64","author":"Han","year":"2021","journal-title":"J. Med. Chem."},{"key":"2026100811083185000_cit42","doi-asserted-by":"publisher","first-page":"15991","DOI":"10.1021\/acs.jmedchem.5c00970","article-title":"Discovery of a novel potent and orally efficacious PROTAC degrader of HPK1 for tumor immunotherapy","volume":"68","author":"Tong","year":"2025","journal-title":"J. Med. Chem."},{"issue":"10","key":"2026100811083185000_cit43","doi-asserted-by":"publisher","first-page":"101062","DOI":"10.1016\/j.xcrp.2022.101062","article-title":"Strategies for the discovery of oral PROTAC degraders aimed at cancer therapy","volume":"3","author":"Han","year":"2022","journal-title":"Cell Rep. Phys. Sci."},{"key":"2026100811083185000_cit44","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41570-025-00784-6","article-title":"Lessons learned in linking PROTACs from discovery to the clinic","volume":"10","author":"Pike","year":"2025","journal-title":"Nat. Rev. Chem."},{"key":"2026100811083185000_cit45","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1021\/acs.jmedchem.8b01631","article-title":"Discovery of ARD-69 as a highly potent proteolysis targeting chimera (PROTAC) degrader of androgen receptor (AR) for the treatment of prostate cancer","volume":"62","author":"Han","year":"2019","journal-title":"J. Med. Chem."},{"key":"2026100811083185000_cit46","unstructured":"Crew, A. P.; Wang, J.; Berlin, M.; Dragovich, P.; Chen, H.; Staben, L.\n          BRM targeting compounds and associated methods of use. U.S. Patent 20,190,300,521 A1, 2019."},{"key":"2026100811083185000_cit47","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s42004-025-01662-4","article-title":"Discovery of KRAS(G12D) selective degrader ASP3082","volume":"8","author":"Yoshinari","year":"2025","journal-title":"Commun. Chem."},{"key":"2026100811083185000_cit48","unstructured":"Cheng, H.; Vernier, J.-M.\n          KRAS inhibitor conjugates. WO 2024040080 A1, 2024."},{"issue":"1","key":"2026100811083185000_cit49","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.chembiol.2017.09.010","article-title":"Lessons in PROTAC design from selective degradation with a promiscuous warhead","volume":"25","author":"Bondeson","year":"2018","journal-title":"Cell Chem. Biol."},{"key":"2026100811083185000_cit50","doi-asserted-by":"publisher","first-page":"4177","DOI":"10.1038\/s41467-023-39904-5","article-title":"Affinity and cooperativity modulate ternary complex formation to drive targeted protein degradation","volume":"14","author":"Wurz","year":"2023","journal-title":"Nat. Commun."},{"key":"2026100811083185000_cit51","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1021\/acs.jmedchem.5c03024","article-title":"Unhooking the hook: Optimization of the Aurora A targeting PROTAC JB170 to CCT400028, an in vitro degrader chemical probe","volume":"69","author":"O\u2019Hanlon","year":"2026","journal-title":"J. Med. Chem."},{"key":"2026100811083185000_cit52","doi-asserted-by":"publisher","first-page":"8281","DOI":"10.1021\/acs.jmedchem.3c00740","article-title":"Physicochemical property determinants of oral absorption for PROTAC protein degraders","volume":"66","author":"Hornberger","year":"2023","journal-title":"J. Med. Chem."},{"key":"2026100811083185000_cit53","doi-asserted-by":"publisher","first-page":"13106","DOI":"10.1021\/acs.jmedchem.4c01017","article-title":"Structural and physicochemical features of oral PROTACs","volume":"67","author":"Schade","year":"2024","journal-title":"J. Med. Chem."},{"key":"2026100811083185000_cit54","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1021\/jm301297f","article-title":"Demystifying brain penetration in central nervous system drug discovery. Miniperspective","volume":"56","author":"Di","year":"2013","journal-title":"J. Med. Chem."},{"key":"2026100811083185000_cit55","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1021\/cn100008c","article-title":"Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties","volume":"1","author":"Wager","year":"2010","journal-title":"ACS Chem. Neurosci."},{"key":"2026100811083185000_cit56","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1021\/acs.jmedchem.3c01781","article-title":"PROTACs targeting BRM (SMARCA2) afford selective in vivo degradation over BRG1 (SMARCA4) and are active in BRG1 mutant xenograft tumor models","volume":"67","author":"Berlin","year":"2024","journal-title":"J. Med. Chem."},{"key":"2026100811083185000_cit57","unstructured":"Liu, J.; Ren, Y.; Tang, J.; Tian, Q.; Song, H.; Yu, W.; Ge, J.\n          Spiro compound, and preparation method therefor and use thereof. WO 2025190158 A1, 2025."},{"key":"2026100811083185000_cit58","unstructured":"Xu, R.; Yang, X.; Zhang, H.; Lu, L.; Zheng, H.; Wang, Z.; Wang, W.; Li, S.; He, J.; Shi, Z.; Wang, D.; Lin, Y.; Li, T.; Fang, L.; Tan, Y.; Xu, Y.; Xia, H.; Lu, Y.; Wu, H.; Zhou, Q.; Lan, H.; Wang, J.; Ding, L.\n          Pan-kras protein targeted degrader compound and use thereof. WO 2025039676 A1, 2025."}],"container-title":["Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.jmedchem.6c01893","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/69\/19\/22671\/68559655\/jm6c01893.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/69\/19\/22671\/68559655\/jm6c01893.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:49:49Z","timestamp":1791474589000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article\/69\/19\/22671\/5433011\/Discovery-of-Potent-and-Selective-VHL-Recruiting"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":58,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2026,9,18]]},"published-print":{"date-parts":[[2026,10,8]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.jmedchem.6c01893","relation":{},"ISSN":["0022-2623","1520-4804"],"issn-type":[{"value":"0022-2623","type":"print"},{"value":"1520-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,18]]}}}